HomeREGULATORY
REGULATORY

Xeljanz’s Ulcerative Colitis Use Up for MHLW Panel Review on April 27
(Apr.16.2018)

A key health ministry panel will discuss on April 27 a label expansion of Pfizer’s Xeljanz (tofacitinib) for the treatment of ulcerative colitis (UC). If given the nod, it will clear the way for the drug to become the first JAK inhibitor carrying an UC indication in Japan ...
(LOG IN FOR FULL STORY)